• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    2/9/23 11:27:43 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email
    SC 13G/A 1 tv01487-naturessunshineprodu.htm SCHEDULE 13G/A naturessunshineproductsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 1)*

    Name of issuer:  Nature's Sunshine Products Inc.

    Title of Class of Securities:  Common Stock

    CUSIP Number:  639027101

    Date of Event Which Requires Filing of this Statement: December 30, 2022

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  639027101

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    6,900

    7.  SOLE DISPOSITIVE POWER

    466,652

    8.  SHARED DISPOSITIVE POWER

    10,724

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    477,376

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    2.49%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Nature's Sunshine Products Inc.

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    2901 West Bluegrass Boulevard, Suite 100
    Lehi, UT 84043

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    639027101

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 9, 2023

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $NATR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & President, Asia Norman Daniel C sold $200,476 worth of shares (9,713 units at $20.64), decreasing direct ownership by 17% to 47,276 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    6/3/26 6:44:18 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, General Counsel Brower Nathan G sold $262,408 worth of shares (12,015 units at $21.84), decreasing direct ownership by 22% to 43,438 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    5/22/26 11:59:55 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fasching Steven J. was granted 4,500 shares, increasing direct ownership by 41% to 15,369 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    5/20/26 12:17:48 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    SEC Filings

    View All

    SEC Form S-8 filed by Nature's Sunshine Products Inc.

    S-8 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    5/15/26 4:52:47 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    5/11/26 8:46:55 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    5/7/26 5:19:52 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson resumed coverage on Nature's Sunshine with a new price target

    DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

    5/7/25 8:37:48 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

    Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

    9/13/24 7:38:59 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

    DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

    3/9/22 9:23:08 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nature's Sunshine Reports Strong First Quarter 2026 Results

    Net Sales up 9% to $122.9 million, GAAP EPS up 16% to $0.29Adjusted EBITDA up 33% to $14.6 million LEHI, Utah, May 07, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary vs. Same Year-Ago Quarter Net sales were up 9% to $122.9 million compared to $113.2 million (up 7% in constant currency).Gross profit margin increased 116 basis points to 73.2% compared to 72.1%.GAAP net income attributable to common shareholders was $5.1

    5/7/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints John Hnanicek as Chief Technology Officer

    LEHI, Utah, April 30, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, today announced that John Hnanicek has been appointed Chief Technology Officer, effective May 4, 2026. Mr. Hnanicek brings decades of senior leadership experience in technology, digital innovation, and e-commerce transformation across leading consumer, retail, and direct-to-consumer organizations. He most recently served as Chief Digital Innovation Officer at Melaleuca, where he led enterprise-wide digital initiatives, technology modernization, and customer innova

    4/30/26 8:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 5:00 p.m. ET

    LEHI, Utah, April 23, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, May 7, 2026, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2026. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question-and-answer period. Date: Thursday, May 7, 2026Time: 5:00 p.m. Eastern

    4/23/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/12/24 10:37:49 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    1/31/24 11:56:05 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/13/23 2:42:04 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    View All

    Nature's Sunshine Appoints John Hnanicek as Chief Technology Officer

    LEHI, Utah, April 30, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, today announced that John Hnanicek has been appointed Chief Technology Officer, effective May 4, 2026. Mr. Hnanicek brings decades of senior leadership experience in technology, digital innovation, and e-commerce transformation across leading consumer, retail, and direct-to-consumer organizations. He most recently served as Chief Digital Innovation Officer at Melaleuca, where he led enterprise-wide digital initiatives, technology modernization, and customer innova

    4/30/26 8:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Erich Fritz as Executive Vice President of Global Supply Chain

    LEHI, Utah, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Erich Fritz has been named Executive Vice President, Global Supply Chain, effective December 8, 2025. Mr. Fritz will report directly to Ken Romanzi, the Company's Chief Executive Officer. Mr. Fritz brings over 40 years of executive experience in operations, supply chain, and business development, with a proven track record of driving growth, operational efficiency, and innovation at leading consumer goods companies. His leadership spans Fortune 500 organizations an

    12/4/25 10:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Kenneth Romanzi as CEO

    Mr. Romanzi Brings Extensive Leadership and Operational Experience at Prominent, Large-Scale Consumer Packaged Goods Companies and Proven Track Record of Driving Growth and Value Creation LEHI, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that its Board of Directors has appointed Kenneth Romanzi to succeed Terrence Moorehead as Chief Executive Officer. Mr. Romanzi will assume the role and become a member of the Nature's Sunshine Board of Directors on October 29, 2025. Mr. Romanzi is an experienced CEO and operator with

    10/15/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Financials

    Live finance-specific insights

    View All

    Nature's Sunshine Reports Strong First Quarter 2026 Results

    Net Sales up 9% to $122.9 million, GAAP EPS up 16% to $0.29Adjusted EBITDA up 33% to $14.6 million LEHI, Utah, May 07, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary vs. Same Year-Ago Quarter Net sales were up 9% to $122.9 million compared to $113.2 million (up 7% in constant currency).Gross profit margin increased 116 basis points to 73.2% compared to 72.1%.GAAP net income attributable to common shareholders was $5.1

    5/7/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets First Quarter 2026 Conference Call for Thursday, May 7, 2026, at 5:00 p.m. ET

    LEHI, Utah, April 23, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, will conduct a conference call on Thursday, May 7, 2026, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the first quarter ended March 31, 2026. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question-and-answer period. Date: Thursday, May 7, 2026Time: 5:00 p.m. Eastern

    4/23/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    LEHI, Utah, March 10, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 4.7% to $123.8 million compared to $118.2 million (up 3.8% in constant currency).GAAP net income attributable to common shareholders of $4.1 million, or $0.23 per diluted share, compared to net loss of $0.3 million, or $(0.02) per diluted share.Adjusted EBITDA up 16% to $11.9 million compar

    3/10/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care